Analysts Issue Forecasts for FOLD Q2 Earnings

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Stock analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for shares of Amicus Therapeutics in a note issued to investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz expects that the biopharmaceutical company will post earnings of ($0.01) per share for the quarter. The consensus estimate for Amicus Therapeutics’ current full-year earnings is ($0.04) per share. Leerink Partnrs also issued estimates for Amicus Therapeutics’ Q4 2025 earnings at $0.07 EPS and FY2025 earnings at $0.04 EPS.

Other equities analysts have also issued research reports about the stock. JPMorgan Chase & Co. boosted their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Bank of America increased their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.88.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $9.51 on Tuesday. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The firm has a market capitalization of $2.84 billion, a price-to-earnings ratio of -27.97, a PEG ratio of 1.43 and a beta of 0.62. The firm’s fifty day simple moving average is $9.66 and its 200 day simple moving average is $10.52. Amicus Therapeutics has a twelve month low of $8.78 and a twelve month high of $14.03.

Institutional Investors Weigh In On Amicus Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Xponance Inc. increased its holdings in shares of Amicus Therapeutics by 5.3% in the 2nd quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 936 shares during the last quarter. Hazlett Burt & Watson Inc. boosted its position in Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Amicus Therapeutics by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 1,884 shares during the period. OLD Second National Bank of Aurora acquired a new position in Amicus Therapeutics during the 3rd quarter valued at approximately $26,000. Finally, AlphaCentric Advisors LLC boosted its position in Amicus Therapeutics by 1.2% during the 3rd quarter. AlphaCentric Advisors LLC now owns 205,000 shares of the biopharmaceutical company’s stock valued at $2,189,000 after purchasing an additional 2,500 shares during the period.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,901 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $11,083,175. The trade was a 0.88 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders sold 22,901 shares of company stock worth $259,863. 2.20% of the stock is currently owned by insiders.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.